Actonel

Company
Procter & Gamble, Hoechst Marion Roussel

Approval Status
Approved April 1998

Treatment for
Paget's Disease

Areas
Diabetes / Endocrinology , Hematology , Musculoskeletal

Actonel has been approved as a new therapy for treating Paget's disease of the bone.

Approval is based on an 18-month, double-blind, active-controlled pivotal trial of 123 patients with moderate-to-severe Paget's disease, which showed disease remission in the majority of patients who received Actonel.

Actonel Drug Information

The Actonel drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top